In Vivo Blockade of Macrophage Migration Inhibitory Factor Ameliorates Acute Experimental Autoimmune Encephalomyelitis by Impairing the Homing of Encephalitogenic T Cells to the Central Nervous System

Claudia M. Denkinger, Michael Denkinger, Jens J. Kort, Christine Metz and Thomas G. Forsthuber

*J Immunol* 2003; 170:1274-1282; doi: 10.4049/jimmunol.170.3.1274
http://www.jimmunol.org/content/170/3/1274

References
This article cites 54 articles, 23 of which you can access for free at:
http://www.jimmunol.org/content/170/3/1274.full#ref-list-1

Subscription
Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

Permissions
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
In Vivo Blockade of Macrophage Migration Inhibitory Factor Ameliorates Acute Experimental Autoimmune Encephalomyelitis by Impairing the Homing of Encephalitogenic T Cells to the Central Nervous System

Claudia M. Denkinger,*‡ Michael Denkinger,* Jens J. Kort,‡‡ Christine Metz,§ and Thomas G. Forsthuber*§

Macrophage migration inhibitory factor (MIF) is a cytokine that plays a critical role in the regulation of macrophage effector functions and T cell activation. However, its role in the pathogenesis of T cell-mediated autoimmune diseases, such as experimental autoimmune encephalomyelitis (EAE), has remained unresolved. In this study, we report that anti-MIF Ab treatment of SJL mice with acute EAE improved the disease severity and accelerated the recovery. Furthermore, the anti-MIF treatment impaired the homing of neuroantigen-reactive pathogenic T cells to the CNS in a VCAM-1-dependent fashion. Interestingly, MIF blockade also decreased the clonal size of the neuroantigen-specific Th1 cells and increased their activation threshold. Taken together, the results demonstrate an important role for MIF in the pathogenesis of EAE/multiple sclerosis and suggest that MIF blockade may be a promising new strategy for the treatment of multiple sclerosis.

Materials and Methods

Animals, Ags, and treatments

Mice were purchased from The Jackson Laboratory (Bar Harbor, ME) and maintained at Case Western Reserve University under specific pathogen-free conditions. All animal procedures were conducted according to guidelines of the Institutional Care and Use Committee of Case Western Reserve University. Female SJL/J and C57BL/6 mice were injected at 6–10 wk of age with the Ags (listed in this section) in CFA. Pertussis toxin (PT; 200 ng; List Biological Laboratories, Campbell, CA) was injected i.p. in 500 µl of saline at 0 and 24 h after injection as indicated in the legend to Fig. 1. PLP peptide aa 139–151 (PLP[139-151]; HSLGKWLGHPDKF) was synthesized by Princeton Biomolecules (Langhorne, PA). IFA was purchased from Life Technologies (Grand Island, NY), and CFA was made by mixing Mycobacterium tuberculosis H 37 Ra (Difco Laboratories, Detroit, MI) at 5 mg/ml into IFA. Ags were mixed with the adjuvant to yield a 2 mg/ml emulsion, of which 50 µl was injected s.c. Neutralizing anti-MIF mAb
The Journal of Immunology

1275

cyte (clone XIV.15.5, IgG1 isotype) was prepared as previously described (20). The isotype matched control mAb (IgG1) was purified similarly using the hybridoma 5D4-11 (HB-49; American Type Culture Collection, Manassas, VA). The Abs were injected i.p. at 0.5 mg/mouse in 0.5 ml of saline as indicated in the figures.

Evaluation of clinical disease in mice
Mice were monitored daily after injection of neuroantigen, and the severity of disease was recorded according to the following scale (21); grade 0, no abnormality; grade 1, limp tail; grade 2, moderate hind limb weakness; grade 3, complete hind limb paralysis; grade 4, quadriplegia or premortem bund state; and grade 5, death. If necessary, food was provided on the cage floor. Where indicated, statistical analysis was performed using the paired t test, comparing the mean EAE grade of all mice in one group with that of the other group at different time points.

Cell preparations from the organs tested and adoptive transfer
Single-cell suspensions from the spleen were prepared as previously described (22). The cells were counted and plated with Ag in HL-1 serum-free medium (BioWhittaker, Walkersville, MD) at 1 × 10^6 cells/well, and tested as indicated in Fig. 5. For adoptive transfer experiments, splenic mononuclear cells from mice immunized as indicated in the figures were prepared as described (22). These cells were subsequently preactivated by incubation with PLP-139-151, at the previously established optimal stimulatory concentration (20 μg/ml) in complete DMEM for 4 days before i.p. injection into the recipient animals.

Cytokine measurements by ELISPOT and computer-assisted ELISPOT image analysis
The ELISPOT assay was performed as described previously (23). Briefly, ELISPOT plates (ImmunoSpot; Cellular Technology, Cleveland, OH) were coated overnight with IFN-γ (R46A2; 4 μ/ml), IL-2 (JS6-1A12; 2 μg/ml), IL-3 (MP2-8SF8; 4 μ/ml), IL-4 (BVD4-1D11; 4 μ/ml), IL-5 (TRFK5; 5 μ/ml) specific capture Ab. The plates were blocked with 1% BSA in PBS for 1 h at room temperature, and then washed four times with PBS. Spleen cells were plated at 10^6 cells/well alone or with Ag (7 μM) in HL-1 medium and cultured for 24 h for IFN-γ, IL-2, or IL-3, or 48 h for IL-4 or IL-5. Subsequently, the cells were removed by washing and the biotinylated detection Ab XMG1.2-biotin (2 μg/ml) for IFN-γ, JS6-5H4-biotin (0.25 μg/ml) for IL-2, MP2-43D11 (0.5 μg/ml) for IL-3, BVD6-2462 (0.2 μg/ml) for IL-4, and TRFK4-biotin (2 μg/ml) for IL-5 were added and incubated overnight. The plate-bound second Ab was then visualized by adding streptavidin-alkaline phosphatase (SAV-AP; DAKO, Carpinteria, CA) and nitroblue tetrazolium/5-bromo-4-chloro-3-indoly phosphate substrate (Bio-Rad, Hercules, CA; Sigma-Aldrich, St. Louis, MO). Image analysis of ELISPOT assays was performed on a Series 1 ImmunoSpot Image Analyzer (Cellular Technology) as described previously (24, 25). In brief, digitized images of individual wells of the ELISPOT plates were analyzed for cytokine spots, based on the comparison of experiments containing T cells and APC with Ag) and control wells (T cells and APC, no Ag). After separation of spots that touched or partially overlapped, nonspecific noise was gated out by applying spot size circularity analysis as additional criteria. Spots that fell within the accepted criteria were highlighted and counted. The stimulation index was calculated by dividing the number of cytokine spots detected in wells pulsed with cognate Ag by the number of cytokine spots in wells without Ag (medium only). The spot number in unimmunized or control mice (irrelevant Ag) was in the same range as that of the medium controls. Where indicated, statistical analysis was performed using the paired t test, χ^2 test, or the Mann-Whitney rank sum test using SigmaStat software (SPSS, Chicago, IL).

Flow cytometry analysis for expression of surface molecules
(CD3, CD4, CD19, and CD11b)
Single-cell suspensions of spinal cord isolates were incubated at 1 × 10^6 cells/sample with 1 μg of the respective FITC- or PE-labeled anti-mouse Abs (BD PharMingen, San Diego, CA) in PBS for 1 h on ice. Cells were washed with PBS and erythrocytes were lysed with Immuno-lyse (Coulter, Miami, FL). The cells were then fixed in Coulter Clone fixative reagent and read on a BD Biosciences FACScan flow cytometer. The flow cytometry data was analyzed using CellQuest software (BD Biosciences).

Histopathology, immunofluorescence staining, and cell counting
At the time of the experiment, the brain and spinal cord of the mice were removed and either preserved in 10% formalin or snap-frozen in 2-methylbutane. Five-micrometer slices of the CNS tissue were prepared and stained with H&E. The tissue was then examined by light microscopy in a blinded fashion by a pathologist and evaluated for the extent of inflammation and graded as follows: −, no inflammation; +/−, a few mononuclear cells; +, organization of inflammatory infiltrates around positive vessels; +++, extensive perivascular cuffing with extension into the subarachnoid space; and ++++, extensive perivascular cuffing with increasing subarachnoid inflammation (21, 26). Immunofluorescence staining of the brain tissue was performed as described (27). In brief, 5-μm sections of snap-frozen brain tissue were fixed with 4% paraformaldehyde and probed with FITC- or PE-conjugated anti-mouse-CD3, -CD4, -CD19, -MAC-1, and -F4/80 Abs (BD PharMingen). Images of Ab-labeled tissue sections were captured using a Leica fluorescence microscope equipped with a CCD camera at ×400 magnification, and image analysis software (Spot 2.0; Diagnostic Instruments, Sterling Heights, MI). Sections were blindly analyzed by two experienced observers as follows: immunostained T cells (CD3), B cells (CD19), and macrophages/microglia (MAC-1, F4/80) were counted on four sections obtained in a standardized fashion from different levels of the neuraxis. On each slide, four inflammatory foci (meningeal, perivascular, between two lobes, and in the gray matter) were selected and scored for the number of cells staining positively for the respective markers. The result was calculated as the mean ± SD of numbers of cells in each category over all lesions counted.

Evaluation of staining intensity
Evaluation of expression of adhesion molecules on brain vessels was performed on CNS tissue sections as described (28) with FITC- or PE-labeled monoclonal VCAM-1 or ICAM-1 Abs (BD PharMingen). Briefly, after immunofluorescence staining for ICAM-1 and VCAM-1, images of brain vessels were captured at ×400 with a Leica fluorescence microscope equipped with a CCD camera and image analysis software (Diagnostic Instruments). For the evaluation of the relative fluorescence intensity, the mean brightness value of the green (FITC) or red (PE) fluorescence channel of the three most intensely stained areas of the vessel was determined using Adobe Photoshop 6.0 (Adobe Systems, San Jose, CA) with a set 200-pixel square area. The background reading in unstained areas was subtracted from these values. Four sections from different levels of the neuraxis were taken. Four vessels from each section were analyzed and the mean ± SEM of the fluorescence intensity for each group of mice was calculated.

Results
Anti-MIF Ab treatment reduces EAE severity, duration, and CNS pathology
The role of MIF in the pathogenesis of EAE has not been studied. To address this question, we induced EAE in SJL/J mice by immunization with the immunodominant H-2^d-restricted PLP peptide PLP-139-151. Subsequently, the mice were randomized into two groups and injected with either anti-MIF or isotype-matched control Abs every other day for 2 wk. The anti-MIF Ab treatment was initiated 6 days after immunization with the PLP peptide because we reasoned that the PLP-139-151-specific T cells were already primed at this time point, and treatment with anti-MIF Abs would therefore elucidate whether or not MIF was required for the induction of EAE by these cells in the CNS.

Interestingly, as shown in Fig. 1a, the injection of anti-MIF Abs significantly reduced clinical EAE symptoms. As shown in Table I, the incidence and mean EAE score of anti-MIF Ab-treated mice were significantly lower as compared with those of control Ab-injected animals (incidence 81.8 vs 100%, respectively; mean EAE score of 2.7 ± 0.2 vs 3.9 ± 0.2), and the disease duration was shorter (7.0 ± 0.7 days vs 10.0 ± 0.4 days, respectively). Moreover, the lethality was significantly decreased (21.2 vs 48.5%, respectively). Hence, the data showed that the treatment was effective when the anti-MIF Abs were injected before the onset of disease.

However, in human MS patients, treatment can begin only after the onset of the disease symptoms. Therefore, we asked whether or not anti-MIF Ab treatment was also efficacious after the onset of
The results for each independent experiment were statistically significant.

Anti-MIF Ab treatment improves EAE. *a,* Six- to 8-wk-old SJL/J mice were immunized with PLP\textsubscript{139–151} in CFA and PT. Mice were randomly assigned into two groups and Abs were injected i.p. every second day before the onset of disease as indicated (\land) on day 6 after immunization. \*b,* EAE was induced as above. Mice were observed for clinical signs of EAE and then randomly assigned to either the anti-MIF Ab-treated group (\bigcirc) or the control Ab-treated group (\bullet). The Abs were injected i.p. every second day after onset of disease as indicated (\land) on day 11 after immunization. \*c,* Groups of SJL/J mice (n = 10 per group) were injected with anti-MIF or control Ab every second day for 5 days. Two days after the last injection, the mice from both groups were adoptively transferred with 5\times 10^6 preactivated PLP\textsubscript{139–151}-specific T cells (short-term T cell lines generated in the absence of Abs) and observed for EAE symptoms. Experiments were performed as outlined in Materials and Methods. Shown are the mean EAE scores for one representative experiment (n = 6–10 mice per group) repeated two to four times with similar results.

EAE symptoms. For this, EAE was induced in SJL mice by immunization with the PLP\textsubscript{139–151} peptide as outlined above. As shown in Fig. 1\*a,* all of the mice developed clinical EAE symptoms by day 9. The mice were then randomized into two groups and injected with either anti-MIF or control Ab starting on day 11 after immunization, i.e., at a time when the disease began to peak. Importantly, the disease symptoms improved rapidly in the anti-MIF Ab-injected mice (Fig. 1\*b,* \bigcirc vs \bullet), and most of the animals recovered completely within 3–4 days. In strong contrast, EAE symptoms continued to worsen in the control Ab-treated mice, and they recovered significantly later (mean EAE scores 2.6 \pm 0.2 in the control mice vs 1.6 \pm 0.2 in the anti-MIF Ab-treated mice; disease duration 14.9 \pm 1.3 vs 8.7 \pm 1.1 days). To delineate anti-MIF Ab effects on theafferent or efferent phase of the autoimmune response in this model, we performed adoptive transfer experiments. As shown in Fig. 1\*c,* groups of naive SJL mice were treated with anti-MIF Abs (\bigcirc) or control Abs (\bullet). Two days after the last injection, the same number of activated PLP\textsubscript{139–151}-reactive T cells (short-term T cell lines generated in the absence of control or anti-MIF Abs) was adoptively transferred into both groups. The data show that the pretreatment of the recipients with anti-MIF Abs ameliorated the EAE course (statistically significant, *p* < 0.005). Moreover, the disease onset in anti-MIF Ab-treated mice was significantly delayed (day 12 for anti-MIF-treated mice vs day 6 for control Ab-treated mice). Hence, the data indicate that the anti-MIF treatment affected the efferent phase of the autoimmune response.

The amelioration of clinical EAE symptoms in anti-MIF Ab-treated mice was reflected by the reduced CNS pathology. As shown in Fig. 2, \*a and \*b,* control Ab-treated mice with actively induced EAE showed extensive perivascular and periventricular inflammation, and the inflammatory infiltrates extended into the CNS parenchyma. The inflammatory cells consisted mainly of CD4+ T lymphocytes and macrophages/microglia (Fig. 2\*c,*). In contrast, anti-MIF Ab-treated mice showed significantly less CNS inflammation, and the infiltrates remained localized to the perivascular space without significant parenchymal infiltration (Fig. 2, \*d–f,*). Similar histologic findings were obtained when the treatment was initiated on day 6, i.e., before the onset of EAE (not shown).

Taken together, the results showed that the anti-MIF Ab treatment ameliorated EAE and reduced disease severity, duration, and CNS pathology. Moreover, the MIF blockade was efficacious for the treatment of acute EAE in mice after the onset of disease symptoms.

Several mechanisms could account for the observed effects of anti-MIF Ab treatment on EAE. First, the Ab treatment could inhibit the recruitment of activated neuroantigen-reactive T cells to the CNS. Second, MIF blockade could affect the priming, clonal expansion, and/or the effector functions of neuroantigen-reactive T cells. Third, MIF immunoneutralization could impair APC effector functions in the CNS, and finally, the treatment could trigger immunoregulatory mechanisms, such as regulatory T cells.

Treatment with anti-MIF Abs impairs T cell migration to the CNS

MIF has been reported to regulate the expression of molecules such as chemokines, chemokine receptors, or adhesion molecules involved in the migration of T cells to sites of inflammation (4–6). Consistent with these reports, we noted a decrease in inflammatory cells in the CNS of anti-MIF Ab-treated mice with EAE (Fig. 2, \*d–f,*). Hence, to test the hypothesis that anti-MIF Ab treatment impaired the migration of pathogenic T cells to the CNS, we quantified the number of CD3+CD4+T cells, B cells, and macrophages

Table 1. Effect of anti-MIF mAb treatment on the development of EAE

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Incidence (%)</th>
<th>Onset (day)</th>
<th>Duration (days)</th>
<th>Clinical Score</th>
<th>Lethality (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control mAb</td>
<td>100.0 (33/33)</td>
<td>10.0 \pm 0.4</td>
<td>10.0 \pm 0.4</td>
<td>3.9 \pm 0.2</td>
<td>48.5 (16/33)</td>
</tr>
<tr>
<td>Anti-MIF mAb</td>
<td>81.8 (27/33)</td>
<td>11.1 \pm 0.3</td>
<td>7.0 \pm 0.7</td>
<td>2.7 \pm 0.2</td>
<td>21.2 (7/33)</td>
</tr>
</tbody>
</table>

* Mice were immunized with 50 \mu g of PLP\textsubscript{139–151}/CFA (i.c.) plus PT (i.p.) and assessed for disease in a blinded fashion as outlined in Materials and Methods. Anti-MIF mAb or control mAb was injected i.p. every other day starting on day 6. The data were obtained in four independent experiments (n = 6–10 mice per group for each experiment). The results for each independent experiment were statistically significant.
in the CNS of anti-MIF or control Ab-treated mice with EAE by immunofluorescence staining and flow cytometry. As shown in Fig. 3, a and b, the number of CD$^3^\text{+}\text{CD}4^+\text{T cells was significantly decreased in the CNS of anti-MIF Ab-treated mice as compared with that of control Ab-injected animals (p < 0.02). However, no significant difference was noted between the two groups in the number of macrophages/microglia (p > 0.05). The number of B cells was below the detection limit. Importantly, the absolute number of cells and the percentage of T cells, B cells, or macrophages in the spleens of anti-MIF or control Ab-treated mice were similar (not shown), indicating that the results were not due to an overall reduction of CD$^4^+\text{T cells by the Ab treatment. Similar results were obtained when the Ab treatment was initiated on day 11 after immunization (not shown), and in studies in which we induced EAE in C57BL/6 mice with myelin oligodendrocyte glycoprotein peptide 35–55 and treated with anti-MIF or control Abs. Hence, the data show that the effects of MIF blockade on EAE are strain- and neuroantigen-independent (data not shown).

**FIGURE 2.** Anti-MIF Ab treatment ameliorates CNS pathology. Histologic analysis of H&E-stained brain sections of representative SJL/J mice with acute EAE treated with control (a–c) or anti-MIF Abs (d–f), starting on day 11 after immunization, was performed as outlined in Materials and Methods (sections obtained on day 14). Control Ab-injected SJL mice with EAE show extensive perivascular inflammation (a) with infiltration into the CNS parenchyma (b), c. Immunofluorescence staining demonstrating CD$^4^+\text{T cells in the CNS parenchyma. MAC-1 cells, but not CD$19^+\text{B cells (not shown), were present. Anti-MIF Ab-injected mice show significantly less perivascular inflammation and no infiltration of inflammatory cells into the parenchyma (d–f). Similar results were obtained in four independent experiments.

**FIGURE 3.** Anti-MIF Ab treatment impairs the migration of CD$^3^\text{+}\text{CD}4^+\text{T cells to the CNS. Six- to 8-wk-old SJL/J mice were immunized with PLP$_{139-151}$ in CFA and PT. Mice were observed for clinical signs of EAE and randomly assigned to either the anti-MIF Ab-treated group (●) or the control Ab-treated group (□). The Abs were injected i.p. every second day starting on day 6. The brains of the mice were removed after 3 wk and stained with monoclonal anti-CD$\text{3}, \text{CD}4, \text{CD}19, \text{CD}11\text{b, or F4/80 Abs. a, Shown are the mean ± SD of the number of cells per brain staining positive for CD3 or CD11b/F4/80 by immunofluorescence histology averaged over four areas for four sections of the brain (n = 10 mice per group). b, Shown are the mean ± SD of the number of CD4- or CD11b-positive cells per 5 × 10$^5$ spinal cord cells measured by flow cytometry (n = 10 mice per group). Experiments were performed as outlined in Materials and Methods. Similar results were obtained in three independent experiments.
To conclude, the results showed that anti-MIF Ab treatment decreased the inflammatory CD4\(^+\) T cell infiltrates in the CNS of mice with EAE. Moreover, the data suggested that the mechanism underlying the efficacy of anti-MIF Ab treatment in EAE involved an impaired migration of encephalitogenic T cells to the CNS.

**Treatment with anti-MIF Abs decreases the expression of VCAM-1 in the CNS of mice with EAE**

The migration of encephalitogenic T cells to the CNS is dependent on the interaction of adhesion molecules, such as very late Ag 4 (VLA-4) on T cells, with VCAM-1-expressed by vascular endothelial cells (4, 29, 30). Therefore, we investigated whether or not the impaired CNS homing of T cells in anti-MIF Ab-treated mice was associated with an altered expression of VCAM-1 or ICAM-1, two of the adhesion molecules implicated in the migration of T cells into the brain.

Interestingly, as shown in Fig. 4, anti-MIF Ab treatment decreased the expression of VCAM-1 on vascular endothelial cells in the CNS, as compared with the control Ab-injected animals (Fig. 4a, left \(\square\) vs left \(\blacksquare\), \(p < 0.005\); Fig. 4b, bottom left vs top left). By contrast, there was no significant difference in the expression of ICAM-1 in both groups (Fig. 4a, right \(\square\) vs right \(\blacksquare\), \(p > 0.05\); Fig. 4b, bottom right vs top right, staining indicated by arrows). Double staining with VCAM-1 and CD31 (platelet endothelial cell adhesion molecule-1) confirmed that VCAM-1 was expressed on endothelial cells (not shown). Furthermore, the levels of CD31 expressed in the CNS of anti-MIF or control Ab-treated mice were similar (not shown), arguing against a significant role for this molecule in the amelioration of EAE in this model.

Together, the data showed that anti-MIF Ab treatment decreased the expression of VCAM-1 in the brain. Furthermore, the results implicated decreased expression of VCAM-1 as the mechanism responsible for the decreased homing of T cells to the CNS in this study.

**The frequencies of PLP\(_{139–151}\)-reactive Th1 cells are decreased in the CNS of anti-MIF Ab-treated mice**

Our results suggested that anti-MIF Ab treatment impaired the homing of T cells to the CNS during EAE. However, the Ab treatment could selectively affect the CNS homing of encephalitogenic PLP\(_{139–151}\)-specific T cells, and/or it could prevent the migration of bystander T cells to this site. Moreover, the treatment could impair the survival of neuroantigen-specific T cells in the CNS. To directly address these questions, we measured the frequencies and cytokine profiles of PLP\(_{139–151}\)-reactive T cells in the CNS at single-cell resolution by computer-assisted cytokine ELISPOT assay. Shown in Fig. 5a are the results of PLP\(_{139–151}\)-immunized SJL mice treated with the anti-MIF Ab during acute EAE (day 11, \(\square\)) or control Ab (\(\blacksquare\)). Recall assays with the cognate Ag were performed 2 wk after immunization. Interestingly, the frequencies of PLP\(_{139–151}\)-reactive IFN-\(\gamma\)-secreting Th1 cells in the CNS were significantly reduced in anti-MIF Ab-treated mice, as compared with the control group (\(p < 0.001\)). Moreover, the data show that the anti-MIF Ab treatment at this time point did not affect the priming of these T cells, because high frequencies of PLP\(_{139–151}\)-reactive T cells could be detected in the spleen of these mice (Fig. 5b). Furthermore, there was no bias toward IL-5 (Fig. 5, a and b).

**FIGURE 4.** Anti-MIF Ab treatment decreases the expression of VCAM-1 in the CNS. Six- to 8-wk-old SJL/J mice were immunized with PLP\(_{139–151}\) in CFA and PT. Mice were observed for clinical signs of EAE, and randomly assigned to either the anti-MIF Ab-treated group (\(\square\)) or the control Ab-treated group (\(\blacksquare\)). The Abs were injected i.p. every second day starting from day 6. The brains of the mice were removed after 3 wk and stained with monoclonal VCAM-1 or ICAM-1 Abs. The relative fluorescence intensity of the three most intensely stained areas of the vessels was determined by digital image analysis as outlined in Materials and Methods. a, Shown are the results of the immunofluorescence staining of the brains showing the mean fluorescence intensity ± SEM averaged over four vessels per each of four sections per brain, averaged over 10 mice per group. Similar results were seen in three independent experiments. b, Shown are representative sections of anti-MIF (bottom) or control Ab-treated mice (top) stained with VCAM-1 (left) or ICAM-1 (right). Staining for the adhesion molecules on the endothelium is indicated by arrows. Expression of VCAM-1 on endothelial cells was confirmed by double staining with CD31 (not shown).
Ab-injected mice (Fig. 6) or control Ab-treated mice required 10- to 100-fold higher concentrations of PLP peptide as compared with T cells from control anti-MIF Ab-treated mice stained by TUNEL technique showed an increase in the number of apoptotic T lymphocytes as compared with those of control Ab-injected mice (data not shown), suggesting that MIF blockade rendered activated neuroantigen-specific T cells more susceptible to in situ apoptosis.

To summarize, the results indicated that the anti-MIF Ab treatment selectively decreased the frequencies of PLP139–151-specific T cells in the CNS. Moreover, the results suggested that, in addition to their impaired homing, the survival of PLP139–151-reactive T cells in the CNS was impaired.

The activation threshold of PLP139–151-reactive T cells is increased in anti-MIF Ab-treated mice with EAE

Treatment of EAE with anti-MIF Abs ameliorated disease and decreased the frequencies of PLP139–151-reactive T cells in the CNS and the spleen. However, in addition, the function of these T cells could have been affected by the treatment. Therefore, we tested the cytokine production of PLP139–151-specific T cells from anti-MIF or control Ab-treated SJL mice as a function of Ag concentration in cytokine ELISPOT recall assays. As shown in Fig. 6, the activation of T cells (production of IFN-γ) recovered from the CNS of anti-MIF Ab-treated mice required 10- to 100-fold higher concentrations of PLP peptide as compared with T cells from control Ab-injected mice (Fig. 6a, □ vs ■, respectively). Similar results were obtained when purified CD4+ T cells from the spleens of both groups were tested with irradiated APCs from untreated naive SJL mice (Fig. 6b, □ vs ■, respectively), indicating that the observed differences were primarily the result of a change in the T cell compartment. Moreover, adoptive-transfer experiments showed that PLP139–151-reactive T cells derived from anti-MIF Ab-treated mice were less pathogenic than were cells from control Ab-treated mice (data not shown).

Taken together, the data show that T cells from anti-MIF Ab-treated mice have an increased activation threshold for stimulation with the PLP139–151 peptide, as compared with T cells from control Ab-treated mice. The results suggested that the loss of PLP139–151-reactive T cells with a high functional avidity could be due to the observed increase in apoptosis in the CNS of anti-MIF Ab-treated mice.

Discussion

In this study, we show for the first time that anti-MIF Abs are highly effective in the treatment of acute EAE. The results indicate that MIF blockade impairs the migration of neuroantigen-reactive T cells to the CNS and decreases their clonal size, while increasing their activation threshold.

The migration of autoreactive T cells to sites of the autoimmune attack is critically dependent on the interaction of adhesion molecules on these cells with their ligands such as VCAM-1, ICAM-1, CD31, and LFA-1 on tissues in the target organ (31–35). Thus, the delayed onset and reduced severity of EAE in anti-MIF-treated mice appeared to be the consequence of the decreased expression of VCAM-1 in the CNS. This interpretation is consistent with reports demonstrating that anti-MIF Ab treatment prevented the up-regulation of VCAM-1 and ameliorated disease in a glomerulonephritis model in rats (36). Similarly, VCAM-1 and VLA-4, its ligand expressed on T cells, have been linked to the ability of neuroantigen-reactive T cells to migrate to the CNS and cause EAE (31). However, in contrast to these results, application of anti-VLA-4 Abs prevented or ameliorated EAE only if it was initiated before the onset of disease (37). Moreover, treatment with anti-VLA-4 Abs during acute disease exacerbated EAE and enhanced the accumulation of T cells in the CNS, which produced higher levels of IFN-γ and IL-2.

Hence, the therapeutic efficacy of anti-MIF Abs during acute EAE may not be only the result of impaired homing of T cells to the CNS due to the down-regulation of VCAM-1. MIF blockade may, in addition, impair the effector functions of T cells and/or microglia/oligodendrocytes, such as the production of cytokines or chemokines. In particular, IFN-γ-inducible protein-10 (IP-10;
CXCL10), macrophage-inflammatory protein-1α (MIP-1α), and monocyte chemoattractant protein-1 (MCP-1) have been implicated in the migration of activated T cells into the CNS during EAE (38–40). Treatment with anti-MIP-1α prevented acute EAE (5), whereas anti-MCP-1 treatment decreased the severity of clinical relapses (41). IP-10-deficient mice showed decreased recruitment of CD4+ and CD8+ T cells into the brain in combination with reduced levels of demyelination upon infection with a neurotropic mouse hepatitis virus, suggesting a role for IP-10 in regulating T cell trafficking into the CNS in vivo (42). Furthermore, MIF induced IL-8 in monocytes and dendritic cells (43), and anti-MIF Ab treatment inhibited MCP-1-induced chemotaxis of human PBMCs (44), indicating a role for MIF in the regulation of chemokine expression. However, we are not aware of direct effects of MIF on IP-10 or MIP-1α, i.e., chemokines relevant to the acute phase of disease that we have investigated. Moreover, we consider it unlikely that the enhanced activation threshold of PLP-specific T cells that we have observed was due to altered levels of chemokines in the CNS, because anti-IP-10 treatment did not affect the activation or pathogenic potential of encephalitogenic T cells (39). In contrast, the reduced expression of VCAM-1 could impair the homing of these cells to the brain, and, in addition, decrease their survival via the deprivation from anti-apoptotic signals (45). Consistent with an additional role for MIF in the survival of autoreactive T cells in the CNS in EAE, we found that anti-MIF Ab treatment dramatically decreased the frequencies of IFN-γ-producing PLP139–151-reactive Th1 cells in the CNS, whereas the frequencies in the spleen were only moderately reduced. Moreover, the activation threshold of PLP-reactive T cells in anti-MIF Ab-treated mice was significantly decreased, suggesting that the treatment affected T cells with high affinity for self-Ag (46). Because MIF has been reported to be important for the priming and activation of T cells (13), impaired recruitment of naive T cells into the effector/memory T cell pool could have contributed to the observed reduction in the frequencies of PLP-reactive T cells. However, the dramatic decrease in PLP139–151-reactive T cells in the CNS was also seen when the anti-MIF Ab treatment was started on day 6 or day 11 after immunization, i.e., at a time point when the majority of PLP-specific T cells was already primed. Moreover, we found that anti-MIF treatment significantly ameliorated EAE and delayed the onset of disease symptoms upon adoptive transfer of activated PLP-reactive T cells. Thus, while impaired priming of naive T cells may have contributed to the lower frequencies of neuroantigen-specific T cells, overall the data show that MIF blockade was dominant in its effect on the effenter phase of the autoimmune response, in particular in the CNS.

We propose that MIF blockade impaired the homing and transmigration of neuroantigen-reactive T cells to the CNS. As a consequence, the autoreactive T cells were deprived of TCR and co-stimulatory molecule-mediated signals necessary for cell activation and/or survival (47–49). Deprived of these signals, the PLP139–151-reactive T cells may have become more susceptible to apoptotic cell death or induction of anergy. Interestingly, VLA-4, the ligand for VCAM-1, has been reported to function as a co-stimulatory molecule (50, 51) and to protect T cells from apoptosis (45). Importantly, the increase in the activation threshold of PLP139–151-specific T cells was also observed when T cells from anti-MIF Ab-injected mice were stimulated with spleen cells from naive mice (not Ab treated, Figs. 5b and 6b) as APCs. Hence, the alterations of T cell effector functions induced by the MIF blockade could not be overcome by normal APCs. However, the anti-MIF Ab treatment could have affected APC effector functions in addition, which we have not yet tested.

Recently, regulatory cells have received renewed interest in the control of autoimmunity (52). Therefore, we tested whether or not a deviation toward the production of regulatory Th2 cytokines occurred in this model, as has been reported for experimental models using mAbs to block B7-1 (53). As shown in Fig. 5, we did not observe a switch toward the production of IL-4, IL-5, or IL-10. Moreover, we found that T cells from anti-MIF Ab-treated mice were not protective (C. Denkinger and T. Forsthuber, unpublished observations), although we did not directly test for TGF-β produced by Th3 cells, or CD25+ regulatory T cells (54). Thus, we hypothesize that the efficacy of anti-MIF Abs in the treatment of EAE is primarily due to its down-modulatory effect on the autoimmune Th1 response.
Importantly, our results showed that anti-MIF Ab treatment was efficacious after the onset of clinical EAE symptoms, and that the effects were not mouse strain- or neuroantigen-dependent. Thus, anti-MIF Abs could provide a promising novel therapy for the treatment of acute MS without requiring exact knowledge of the nature of the neuroantigens targeted by the autoimmune T cells. This is a major advantage over other current attempts at Ag-specific immunotherapies, such as altered peptide ligands.

Acknowledgments

We thank Drs. A. Stavitsky, Edward Spack, and K. Weiseltief for critically reading the manuscript, Dr. E. Pearlman for help with the VCAM-1 staining, and Carey Shive and Rocio Guardia for excellent technical assistance. This work is part of the doctoral thesis of C. Denkinger and is supported by Dr.

Thomas Huenig (Institute of Virology and Immunology, University of W¨zburg).

References


